BA1201 / Luye Group, Shandong Boan Biotechnology - LARVOL DELTA

Application Proof of Shandong Boan Biotechnology Co., Ltd (HKEXnews) - "'We received the IND approval for BA1105 from the NMPA in September 2021, and are currently conducting the Phase 1 clinical trial. We plan to complete the ongoing Phase 1 clinical trial in December 2023... We were conducting the pre-clinical study of BA1301 as of the Latest Practicable Date, and we plan to submit the IND application in the first half of 2023...We received the IND approval for BA1201 from the CDE in December 2021. We plan to initiate the Phase 1 clinical trial in China by the first half of 2022 and complete the Phase 1 clinical trial in December 2023'."

New P1 trial • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor